RNA gets CRISPR
How Locana is using CRISPR to go after RNA-driven diseases
Two of the outstanding hurdles for CRISPR-based gene editing are the safety concerns of permanently changing the cell’s DNA and the efficacy limitations of relying on natural DNA repair mechanisms to fix the cuts. Locana Inc. is circumventing both problems by targeting CRISPR-Cas9 to RNA, and is building a pipeline for treating RNA-driven diseases.
The technology is based on work by interim CEO Gene Yeo and his colleagues at the